GO:2000402 negative regulation of lymphocyte migration: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000402 describes any process that stops, prevents or reduces the frequency, rate or extent of lymphocyte migration, a critical brake on immune cell trafficking.
• The RacGAP protein FilGAP is a direct negative regulator of chemokine-promoted lymphocyte migration, acting through Rac1 inactivation.
• Tumor-derived and stromal signals, including FGFR-dependent cancer-associated fibroblast activity, can suppress T cell infiltration into tumors.
• Epstein-Barr virus can dysregulate B cell migration and diapedesis via FAK-dependent chemotaxis pathways, overriding normal negative regulation.
• METTL3 inhibition restores PD-L1 expression and CD8+ T-cell cytotoxic function in immunotherapy-treated gastric cancer, linking RNA methylation to lymphocyte trafficking.
• ST3GAL1 and betaII-spectrin pathways control CAR T cell migration to target tumors, highlighting glycosylation and cytoskeletal control of lymphocyte motility.
Description
Lymphocyte migration is the directed movement of T cells, B cells and natural killer cells through blood, lymphatics and tissues, and it is essential for immune surveillance and adaptive immunity. However, uncontrolled or misdirected lymphocyte migration contributes to autoimmunity, chronic inflammation and tumor immune evasion. The Gene Ontology term GO:2000402, negative regulation of lymphocyte migration, captures the biological processes that stop, prevent or reduce the frequency, rate or extent of this movement. Understanding this term is therefore central to immunology, cancer biology and therapeutic development. Mechanistically, negative regulation of lymphocyte migration can occur through chemokine receptor desensitization, inactivation of small GTPases such as Rac1, modulation of integrin adhesiveness, and changes in cytoskeletal dynamics. For example, the RacGAP protein FilGAP directly inhibits chemokine-promoted lymphocyte migration by inactivating Rac1. In the tumor microenvironment, FGFR blockade can boost T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts, effectively relieving a suppressive signal that limits lymphocyte entry. Viral pathogens such as Epstein-Barr virus can also perturb B cell migration and diapedesis via FAK-dependent chemotaxis pathways, illustrating how pathogens may override normal negative regulatory checkpoints. Researchers study GO:2000402 to identify molecular brakes on lymphocyte trafficking, to understand how tumors exclude immune cells, and to design therapies that either enhance or restrain lymphocyte migration as needed.
negative regulation of lymphocyte migration At A Glance
| GO ID | GO:2000402 |
|---|---|
| GO term | negative regulation of lymphocyte migration |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops, prevents or reduces the frequency, rate or extent of lymphocyte migration |
| Example regulator | FilGAP (RacGAP protein) negatively regulates chemokine-promoted lymphocyte migration |
| Disease relevance | Tumor immune evasion, autoimmunity, viral immune dysregulation |
| Related process | Regulation of chemotaxis, Rac1 GTPase signaling, integrin adhesion |
| Research methods | Live imaging, chemotaxis assays, single-cell RNA-seq, CRISPR screens |
What Is GO:2000402?
According to the Gene Ontology, GO:2000402 (negative regulation of lymphocyte migration) is defined as any process that stops, prevents or reduces the frequency, rate or extent of lymphocyte migration. In other words, it encompasses all molecular and cellular events that act as brakes on the movement of lymphocytes, whether by dampening chemokine sensing, reducing cytoskeletal rearrangement, decreasing adhesion to endothelium, or promoting retention in lymphoid organs.
Why Is negative regulation of lymphocyte migration Important in Cell Biology?
Negative regulation of lymphocyte migration is important because it determines whether immune cells reach their targets or are retained inappropriately. In cancer, suppression of T cell migration into tumors is a major mechanism of immune evasion, and overcoming this brake can improve immunotherapy responses. In viral infections such as Epstein-Barr virus, pathogen-driven changes in B cell migration can promote dissemination and immune dysregulation. In cell therapy, the ability of CAR T cells to migrate to tumors is controlled by glycosylation and cytoskeletal pathways, and understanding negative regulation can guide engineering of more effective therapeutic cells. Thus, GO:2000402 sits at the intersection of basic immunology, oncology, virology and cell therapy.
• Controls immune surveillance by limiting where and when lymphocytes migrate.
• Contributes to tumor immune evasion when T cell infiltration is suppressed.
• Influences immunotherapy outcomes, including anti-PD-L1 and anti-PD-1 responses.
• Is subverted by pathogens such as Epstein-Barr virus to alter B cell trafficking.
• Regulates CAR T cell migration to target tumors, affecting cell therapy efficacy.
• Plays a role in sepsis-associated disruption of B-1a cell homeostasis.
• Involves small GTPase signaling, especially Rac1 inactivation by FilGAP.
• Can be studied with single-cell RNA expression atlases of normal and tumor tissues.
• Provides targets for modulating autoimmune and inflammatory cell infiltration.
• Links RNA modification pathways such as METTL3 to lymphocyte function.
What Happens During negative regulation of lymphocyte migration?
Initiation by chemokine and adhesion signals
In simple terms: Lymphocytes normally start moving when they sense chemical signals called chemokines.
Lymphocyte migration begins when chemokines activate G-protein-coupled receptors on the lymphocyte surface, triggering inside-out signaling that activates integrins and promotes adhesion to endothelial cells. This step is required for lymphocytes to arrest on blood vessel walls and begin diapedesis. Negative regulation of lymphocyte migration can act at this initiation stage by dampening chemokine receptor signaling or reducing integrin activation, thereby preventing the cell from receiving or responding to migratory cues.
Rac1 inactivation by FilGAP
In simple terms: A protein called FilGAP puts a brake on the molecular motor Rac1, which slows lymphocyte movement.
The RacGAP protein FilGAP is a direct negative regulator of chemokine-promoted lymphocyte migration. FilGAP inactivates Rac1, a small GTPase that drives actin cytoskeletal rearrangement and membrane protrusion during cell migration. By converting Rac1 to its inactive GDP-bound state, FilGAP reduces the frequency and extent of lymphocyte migration in response to chemokines. This represents a key molecular mechanism for GO:2000402.
Cytoskeletal remodeling and cell polarity
In simple terms: To move, lymphocytes must reorganize their internal skeleton; negative regulation can freeze this reorganization.
Migrating lymphocytes require dynamic actin and microtubule remodeling to establish front-rear polarity and generate traction forces. Negative regulation of lymphocyte migration can interfere with these cytoskeletal changes, for example by stabilizing actin filaments or preventing the localized activation of Rac1 and related GTPases. The ST3GAL1 and betaII-spectrin pathways also control CAR T cell migration to target tumors, indicating that glycosylation-dependent cytoskeletal organization is part of the regulatory landscape.
Modulation by the tumor microenvironment
In simple terms: Tumors can send signals that stop immune cells from entering.
Cancer-associated fibroblasts and tumor-derived factors can suppress T cell infiltration into tumors. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts, suggesting that FGFR signaling in the stroma contributes to negative regulation of lymphocyte migration. This highlights how the tumor microenvironment can actively enforce GO:2000402 to evade immune attack.
Pathogen-driven dysregulation
In simple terms: Some viruses can override the normal brakes on lymphocyte movement.
Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways. This indicates that pathogens can interfere with the normal negative regulation of lymphocyte migration, promoting aberrant trafficking. Understanding these mechanisms may reveal how to restore normal migratory control in virus-associated diseases.
Key Genes Involved in GO:2000402 negative regulation of lymphocyte migration
The following genes and proteins have been experimentally linked to negative regulation of lymphocyte migration or to lymphocyte trafficking pathways relevant to GO:2000402.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ARHGAP24 (FilGAP) | RacGAP that inactivates Rac1 and negatively regulates chemokine-promoted lymphocyte migration | Direct negative regulator of lymphocyte migration; target for modulating Rac1 activity |
| RAC1 | Small GTPase driving actin remodeling and cell migration; inactivated by FilGAP | Central node in migratory signaling; downstream effector of negative regulation |
| FGFR | Receptor tyrosine kinase; stromal FGFR signaling limits T cell infiltration in breast cancer | Target for boosting T cell entry into tumors |
| METTL3 | RNA methyltransferase; inhibition restores PD-L1 and CD8+ T-cell function in gastric cancer | Links RNA modification to lymphocyte migration and immunotherapy |
| ST3GAL1 | Sialyltransferase controlling CAR T cell migration to tumors | Glycosylation-dependent regulation of lymphocyte trafficking |
| SPTBN1 (betaII-spectrin) | Cytoskeletal protein involved in CAR T cell migration | Cytoskeletal control of lymphocyte motility |
| PTK2 (FAK) | Kinase mediating EBV-induced B cell migration and diapedesis | Pathogen-driven dysregulation of lymphocyte migration |
| CD274 (PD-L1) | Immune checkpoint ligand; expression restored by METTL3 inhibition | Connects lymphocyte migration regulation to checkpoint immunotherapy |
| SIGLEC-G | Inhibitory receptor on B-1a cells; targeted by neutrophils in sepsis | Regulates B-1a cell homeostasis and migration in sepsis |
| CD8A | Marker of cytotoxic T cells whose function is restored by METTL3 inhibition | Readout for T cell migration and cytotoxicity |
| CXCR4 | Chemokine receptor commonly involved in lymphocyte trafficking | Chemokine sensing upstream of negative regulation |
| CCR7 | Chemokine receptor guiding lymphocyte homing to lymphoid organs | Context for chemokine-promoted migration assays |
| ITGB1 (Integrin beta1) | Adhesion receptor required for lymphocyte arrest and migration | Target of inside-out signaling during migration |
| CDC42 | Rho GTPase family member involved in cytoskeletal dynamics | Potential modifier of migratory responses |
| RHOА | Rho GTPase regulating actomyosin contraction | Downstream of chemokine signaling in migration |
| VAV1 | Guanine nucleotide exchange factor for Rac1 | Upstream activator counteracted by FilGAP |
| PIK3CD | PI3K catalytic subunit in lymphocytes | Signaling node in chemokine responses |
| PTEN | Phosphatase that opposes PI3K signaling | Potential negative regulator of migratory signaling |
How Is negative regulation of lymphocyte migration Regulated?
Negative regulation of lymphocyte migration is itself regulated at multiple levels. Chemokine receptor desensitization and internalization reduce the cell's sensitivity to migratory cues. Small GTPase cycles are controlled by the opposing activities of guanine nucleotide exchange factors (GEFs) such as VAV1 and GTPase-activating proteins (GAPs) such as FilGAP, which inactivates Rac1. In the tumor microenvironment, stromal FGFR signaling can suppress T cell infiltration, effectively enforcing negative regulation. RNA modifications, such as METTL3-mediated m6A methylation, can influence lymphocyte function and PD-L1 expression, indirectly affecting migratory capacity. Glycosylation pathways involving ST3GAL1 and cytoskeletal proteins such as betaII-spectrin also modulate CAR T cell migration to tumors. Finally, pathogens like Epstein-Barr virus can hijack FAK-dependent pathways to override normal negative regulation.
negative regulation of lymphocyte migration and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGFR | Triple-negative breast cancer immune evasion | Syngeneic breast cancer mouse models with FGFR blockade |
| METTL3 | Gastric cancer immunotherapy resistance | Gastric cancer cell lines and mouse models with METTL3 inhibition |
| PTK2 (FAK) | Epstein-Barr virus-associated B cell migration | EBV-infected B cell lines and FAK inhibitors |
| ST3GAL1 | CAR T cell therapy for solid tumors | CAR T cells with ST3GAL1 knockout or overexpression |
| SIGLEC-G | Sepsis and B-1a cell homeostasis | Sepsis mouse models and Siglec-G knockout mice |
Cancer immune evasion
Tumors can exclude lymphocytes by promoting negative regulation of lymphocyte migration. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts, indicating that stromal FGFR signaling contributes to T cell exclusion. METTL3 inhibition restores PD-L1 expression and CD8+ T-cell cytotoxic function in immunotherapy-treated gastric cancer, linking RNA methylation to lymphocyte function and potentially to trafficking. These findings suggest that targeting negative regulatory pathways could improve immunotherapy responses.
Viral immune dysregulation
Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways. This viral subversion of normal migratory control can promote dissemination and immune dysregulation, highlighting the importance of understanding GO:2000402 in infectious disease.
Sepsis and innate-like B cells
Neutrophils disrupt B-1a cell homeostasis by targeting Siglec-G to exacerbate sepsis. B-1a cells are a specialized lymphocyte population, and their altered homeostasis may involve changes in migration and retention. This links negative regulation of lymphocyte migration to sepsis pathophysiology.
Cell therapy and CAR T cells
ST3GAL1 and betaII-spectrin pathways control CAR T cell migration to target tumors. Understanding these pathways can guide engineering of CAR T cells with improved tumor infiltration, directly relevant to GO:2000402.
From negative regulation of lymphocyte migration-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FilGAP negatively regulate lymphocyte migration? | FilGAP knockout or overexpression in T cell lines and primary lymphocytes |
| Does FGFR blockade enhance T cell infiltration? | Syngeneic breast cancer mouse models treated with FGFR inhibitors |
| Does METTL3 inhibition restore CD8+ T-cell function? | Gastric cancer models with METTL3 knockout or inhibitor treatment |
| Does ST3GAL1 control CAR T cell migration? | CAR T cells with ST3GAL1 knockout or overexpression |
| Does FAK mediate EBV-induced B cell migration? | EBV-infected B cells with FAK knockout or inhibitors |
| Does Siglec-G regulate B-1a cell homeostasis in sepsis? | Siglec-G knockout mice subjected to sepsis models |
How to Study the negative regulation of lymphocyte migration Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Frequency and rate of lymphocyte migration toward chemokines | Testing negative regulators like FilGAP |
| Live cell imaging | Dynamic movement and polarity of lymphocytes | Visualizing cytoskeletal changes during migration |
| Single-cell RNA-seq | Gene expression profiles of lymphocytes in tissues | Identifying migratory signatures in breast cancer |
| CRISPR knockout screening | Genes required for or inhibiting migration | Discovering novel negative regulators |
| Phosphoproteomics | Signaling changes downstream of chemokine receptors | Mapping Rac1 pathway alterations |
| Flow cytometry | Surface markers and adhesion molecule expression | Assessing integrin activation states |
| In vivo adoptive transfer | Lymphocyte trafficking to tissues | Testing tumor infiltration in mouse models |
| CAR T cell migration assay | Migration of engineered T cells to tumors | Optimizing cell therapy |
Live imaging and chemotaxis assays
Live cell imaging and transwell chemotaxis assays are used to measure the frequency, rate and extent of lymphocyte migration in response to chemokines. These methods can quantify negative regulation by comparing migration of control versus genetically modified lymphocytes, such as FilGAP knockout or overexpression cells.
Single-cell RNA sequencing
Single-cell RNA expression atlases of normal, preneoplastic and tumorigenic states in the human breast provide a framework for identifying migratory gene signatures in lymphocytes within tissues. Such atlases can reveal how negative regulators of migration are expressed across cell states.
CRISPR screens and functional genomics
CRISPR library screening can identify genes that negatively regulate lymphocyte migration. By knocking out candidate genes in T cells or B cells and measuring migration, researchers can discover novel regulators. This approach is particularly useful for uncovering pathways such as those involving Rac1, FilGAP and cytoskeletal proteins.
Proteomics and phosphoproteomics
Proteomic and phosphoproteomic analyses can measure changes in signaling downstream of chemokine receptors and adhesion molecules, revealing how negative regulators such as FilGAP alter Rac1 activity and cytoskeletal dynamics. These methods complement functional migration assays.
How CRISPR Can Be Used to Study GO:2000402 negative regulation of lymphocyte migration
Knockout
CRISPR knockout of candidate negative regulators such as ARHGAP24 (FilGAP) can be used to test whether loss of function increases lymphocyte migration. Knockout of ST3GAL1 in CAR T cells can reveal its role in migration to tumors. These experiments directly assess the contribution of specific genes to GO:2000402.
Point Mutation
Point mutations can be introduced into genes like RAC1 to study specific residues required for GTP hydrolysis or interaction with FilGAP. Such models help dissect the molecular mechanism of negative regulation without completely abolishing protein function.
Knock-in
Knock-in of tagged versions of FilGAP or Rac1 allows visualization and biochemical isolation of these proteins in lymphocytes. Tagged knock-in models can be used to track localization and interactions during migration assays.
Overexpression
Overexpression of FilGAP or other negative regulators can suppress lymphocyte migration and confirm their function in vitro and in vivo. Overexpression of ST3GAL1 or betaII-spectrin can also modulate CAR T cell migration.
How EDITGENE Supports negative regulation of lymphocyte migration Research
Researchers studying negative regulation of lymphocyte migration-related genes often need to determine whether a candidate gene is causally involved in suppressing or altering lymphocyte trafficking. EDITGENE provides CRISPR-based cell model services to enable precise genetic perturbations for such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lymphocyte migration research.
Frequently Asked Questions About negative regulation of lymphocyte migration
What is GO:2000402?
GO:2000402 is the Gene Ontology term for negative regulation of lymphocyte migration, defined as any process that stops, prevents or reduces the frequency, rate or extent of lymphocyte migration.
What genes are involved in negative regulation of lymphocyte migration?
Key genes include ARHGAP24 (FilGAP), RAC1, FGFR, METTL3, ST3GAL1, SPTBN1, PTK2 (FAK) and SIGLEC-G, among others.
How does FilGAP regulate lymphocyte migration?
FilGAP is a RacGAP that inactivates Rac1, thereby reducing chemokine-promoted lymphocyte migration.
What diseases are linked to negative regulation of lymphocyte migration?
Cancer immune evasion, viral infections such as Epstein-Barr virus, sepsis and challenges in CAR T cell therapy are linked to this process.
How can I study negative regulation of lymphocyte migration in the lab?
Common methods include transwell chemotaxis assays, live imaging, CRISPR knockout screens, single-cell RNA-seq and phosphoproteomics.
What is the role of the tumor microenvironment in lymphocyte migration?
The tumor microenvironment can suppress T cell infiltration; for example, FGFR signaling in cancer-associated fibroblasts limits T cell entry into triple-negative breast cancer.
Does METTL3 affect lymphocyte migration?
METTL3 inhibition restores PD-L1 expression and CD8+ T-cell cytotoxic function in gastric cancer, indirectly linking RNA methylation to lymphocyte function and trafficking.
How does Epstein-Barr virus affect B cell migration?
EBV induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways, overriding normal negative regulation.
What is the role of ST3GAL1 in CAR T cell migration?
ST3GAL1 and betaII-spectrin pathways control CAR T cell migration to target tumors, affecting cell therapy efficacy.
Can CRISPR be used to study negative regulation of lymphocyte migration?
Yes, CRISPR knockout, knock-in, point mutation and overexpression models can be used to dissect gene function in lymphocyte migration.
Conclusion
GO:2000402, negative regulation of lymphocyte migration, is a fundamental biological process that controls immune cell trafficking and has broad implications for cancer, infectious disease, sepsis and cell therapy. Key molecular players such as FilGAP, Rac1, FGFR, METTL3, ST3GAL1 and FAK provide entry points for experimental interrogation. Understanding how these pathways restrain lymphocyte movement may lead to new strategies for enhancing tumor immunity or dampening pathological inflammation.
References
- 1. Pal B et al.. 2021. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast.. EMBO J 40(11):e107333 PMID: 33950524
- 2. Herbst RS et al.. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.. Nature 515(7528):563-7 PMID: 25428504
- 3. Wu Y et al.. 2022. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.. Theranostics 12(10):4564-4580 PMID: 35832090
- 4. Delecluse S et al.. 2025. Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways.. Nat Commun 16(1):4581 PMID: 40389409
- 5. Fang M et al.. 2025. METTL3 Inhibition Restores PD-L1 Expression and CD8+ T-cell Cytotoxic Function in Immunotherapy-Treated Gastric Cancer.. Cancer Immunol Res 13(7):1037-1052 PMID: 40299705
- 6. Iida T et al.. 2016. The RacGAP protein FilGAP is a negative regulator of chemokine-promoted lymphocyte migration.. FEBS Lett 590(10):1395-408 PMID: 27130700
- 7. Hong Y et al.. 2023. ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.. Nat Immunol 24(6):1007-1019 PMID: 37069398
- 8. Tan C et al.. 2024. Neutrophils disrupt B-1a cell homeostasis by targeting Siglec-G to exacerbate sepsis.. Cell Mol Immunol 21(7):707-722 PMID: 38789529
